ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 March 2008

Arch Dis Child. Published Online First: 15 June 2007. doi:10.1136/adc.2007.116079
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
adc.2007.116079v1
93/3/226    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abeyagunawardena, A. S
Right arrow Articles by Trompeter, R. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abeyagunawardena, A. S
Right arrow Articles by Trompeter, R. S

Original articles

Increasing the dose of Prednisolone during viral infections reduces the risk of relapse in Nephrotic Syndrome: a randomised controlled trial

Asiri S Abeyagunawardena 1* and Richard S Trompeter 2

1 Department of Paediatrics, University of Peradeniya, Sri Lanka
2 Great Ormond Street Children's Hospital, United Kingdom

* To whom correspondence should be addressed. E-mail: asiri26{at}hotmail.com.

Accepted 27 May 2007


*   Abstract

Relapse of nephrotic syndrome (NS) are frequently triggered by viral upper respiratory tract infections (URTI’s), possibly mediated by cytokine release. The hypothesis that a small and short term increase in the dose of prednisolone will reduce the release of cytokines and thereby reduce the risk of relapse was tested by a randomised double blind placebo controlled cross over trial.

Sequential patients receiving low dose (<0.6mg/kg) prednisolone on alternate day as maintenance therapy were recruited. At the first sign of a presumed viral URTI, all children were examined and randomly allocated to take medicine A or B (containing either prednisolone (5mg) or placebo tablets) with the first viral URTI and vice versa with the second. If criteria to diagnose a viral URTI were met, the new medicine was prescribed on alternate day for one week at the same dosage the patient was taking prednisolone on an alternate day basis. A freshly voided urine sample was tested each morning and presence of 3 + proteinuria for three consecutive days was diagnostic of relapse.

48 patients were recruited and 40 completed the trial. 29 male ; 11 female. Age at entry ranged from 1.5 to 13.2 (median 5.3) years. The relapse rate following viral URTI was 19/40 (47.5%) in the placebo group and 7/40 (17.5%) relapses in the prednisolone group. p = 0.014 (2 sided probability using Fisher’s Exact Test).

Prescribing prednisolone daily for 7 consecutive days at the same dose that a patient is receiving on an alternate day basis at the onset of a presumed viral URTI, significantly reduces the risk of relapse in children with steroid dependant NS.


Keywords: Nephrotic Syndrome, glucocorticoid therapy, proteinuria, relapse, viral infections







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health